(cyclohex-2-enyl)(cyclohexyl)methoxymethane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (cyclohex-2-enyl)(cyclohexyl)methoxymethane
• 英文别名: 3-[Cyclohexyl(methoxy)methyl]cyclohexene；3-[cyclohexyl(methoxy)methyl]cyclohexene
• 化学式: C₁₄H₂₄O
• 分子量: 208.344
• InChiKey: QTSKPDGSVUWZOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  溴代环己烷 在 三氟甲磺酸 、 tetrabutylammonium tetrafluoroborate 、 仲丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 、 环己烷 为溶剂， 反应 1.25h， 生成 (cyclohex-2-enyl)(cyclohexyl)methoxymethane
  参考文献：
  名称：

  烷氧基碳鎓离子的电氧化生成和积累及其与碳亲核试剂的反应

  摘要：

  DOI：

  10.1021/ja002123p

文献信息

• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• 9-membered fused ring derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10233156B2

  公开（公告）日：2019-03-19

  The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

  本发明的目的是提供具有 ACC2 选择性抑制活性的新型化合物。此外，本发明还提供了一种包含该化合物的药物组合物。 式的化合物： 或其药学上可接受的盐、 其中，R1 是由式表示的取代或未取代的融合芳香杂环基： 其中 环 B 是 5 元环，环 C 是 6 元环； 环 A 是取代或未取代的非芳香族碳环或类似物； -L1-是-O-(CR6R7)m-或类似物； -L2-是-O-(CR6R7)n-或类似物； 每个 R6 独立地为氢或类似物 每个 R7 独立地为氢或类似物； 每个 m 独立地为 0、1、2 或 3 的整数 每个 n 独立地为 1、2 或 3 的整数； R2 是取代或未取代的烷基； R3 是氢或取代或未取代的烷基； R4 是取代或未取代的烷基羰基或类似物。
• NOVEL ALKYLENE DERIVATIVES
  申请人：SHIONOGI & CO., LTD.

  公开号：US20160257641A1

  公开（公告）日：2016-09-08

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R 1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L 1 - is —O—(CR 6 R 7 )m- etc., -L 2 - is —O—(CR 6 R 7 )n- etc., each R 6 and R 7 are independently hydrogen, halogen etc., R 2 is substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is substituted or unsubstituted alkylcarbonyl etc.
• 9-MEMBERED FUSED RING DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20180079727A1

  公开（公告）日：2018-03-22

  The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R 1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L 1 - is —O—(CR 6 R 7 )m- or the like; -L 2 - is —O—(CR 6 R 7 )n- or the like; each R 6 is independently hydrogen or the like; each R 7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R 2 is substituted or unsubstituted alkyl; R 3 is hydrogen or substituted or unsubstituted alkyl; R 4 is substituted or unsubstituted alkylcarbonyl or the like.